Abstract
Introduction
Hemangiomas are congenital vascular lesions common in head and neck region. Usually are seen as single lesions, but they may be presented as multiple lesions. [1] Most congenital hemangiomas spontaneously regress at young ages. When this regression does not occur, or a lesion appears in older adults several treatments are offered. [2] Hemangiomas treatment is frequently necessary especially when local pain, bleeding, phonetic or esthetic problems are reported, larger lesions may also lead to facial disfigurement. [3, 4] Several therapies such as use of steroids, propanol, interferon alpha, sclerotherapy, chemotherapy, embolization, surgical excision, cryotherapy and high frequency laser removal may be performed to treat hemangiomas. [2, 5, 6] Sclerotherapy performed with the injection of sclerosing substances is presented as an easier technique with few complications. It presents several advantages when compared to other therapies since this procedure is simple, not aggressive, effective and has a low cost. [7, 8] Recently, ethanolamine oleate (EO) has been used as a sclerosing agent to treat facial hemangiomas with slow involution and low flow. [9] This product induces endothelium inflammatory injury, which promotes vessels fibrosis. [10, 11] The aim of this research was to analyze the results of the sclerosing agent 5% EO used to treat oral hemangiomas (OHEM) and obtain the percentage of recurrences after sclerotherapy.
Materials and Methods

Sclerotherapy
Sclerosing therapy consisted of the application of 5% EO with a short needle insulin syringe 1 ml, 10 mm, slowly applied at the lesion periphery. Drug injection stopped when resistance was felt during the application, not exceeding 1 ml of the solution. A 15 days interval between each application was carried out until clinical resolution of the lesion had occurred.
Patient's selection and recurrence evaluation
Lesions that were clinically diagnosed as hemangiomas, <20 mm in diameter, located in the oral region and treated with 5% EO from 1998 to 2008 were retrieved from the Oral Pathology service database of the Federal University of Espírito Santo (Vitória, Brazil).
Treated patients were scheduled for reevaluation and following data were tabulated from patient's file: Age, sex, race, OHEM location, lesion diameter, number of sclerotherapy sessions, lesion regression and side effects. A blinded investigator performed the reevaluation and presence of recurrence were recorded. Patients who were willing to participate in the research and signed the term of free and informed consent were included in this study.
Results
After analyzing 1.333 files, 42 (3.1%) patients presented one or more OHEM lesions with a total of 68 treated lesions [ Table 1 ]. A total of 47 (69.2%) lesions from 25 patients were treated through sclerotherapy with 5% EO. Surgery was performed in only two lesions (2.9%) and another 19 (27.9%) OHEM did not go through invasive treatment due to patient's health status and were followed up.
All 25 patients treated with sclerotherapy were recruited to reevaluation. Ten were present at the new review appointment, and 20 lesions were reevaluated. Data regarding these lesions and patient's characteristics are present in Table 2 . Most lesions were located either in the lips or tongue.
Size of the lesions prior to treatment ranged from 2 to 20 mm, sclerotherapy is indicated in small and medium size lesions so larger lesions were not included in this study. The quantity injected of the solution varied from 0.1 to 1 ml (mean 0.3 ml ± 0.1) and a total of 42 sclerotherapy sessions were performed. Usually, lesions ≤5 mm needed one session to regress and lesions >5 mm healed more frequently in two or more sessions [ Table 3 ].
Treated lesions that diminished in a high proportion but a small residual altered tissue c could be clinically observed were classified as lesions that underwent partial regression. If there were no signs of remnants of the OHEM, it was concluded that it went through the complete sclerosis, and complete regression was recorded. Most lesions healed properly, and few treated cases were classified as a partial regression of the lesion. At the new review appointment, no remnants of the treated lesions that did not recur were seen.
The average time between last application review and reevaluation was 31 (±3) months. Recurrence was present in 2 (10%) of the 20 lesions [ Table 4 ], these lesions presented an increased flow and were present in the same patient.
Discussion
Congenital hemangiomas usually regress at young ages, and most of them do not require treatment. [12] Although these regressions occur, 40% of this lesions leave significant disfigurement needing posterior intervention. [13, 14] Sclerosing agent's use and ressective surgery are the most used techniques in the treatment of OHEM. Surgical excision of OHEM has a high risk of hemorrhage, so general anesthesia is usually performed. [9] The elimination of surgical trauma and less risk of uncontrollable bleeding are the main advantages of sclerotherapy. It can be performed in an ambulatory with or without local anesthesia. Injections of sclerosing agents may also be used pre-surgically to reduce lesions size and facilitate excision when surgery is necessary. [15] EO as a sclerosing agent has lower recurrence rate than surgical excision, it is easier to perform, has a low cost and presents few collateral effects. [7, 16] Treatment's choice should take into account lesions size, location and duration, patients age, hemodynamics of the lesion through the observation of blood flow, and the feasibility of the technique to be used. [17] Sclerotherapy for the treatment of vascular lesions is documented in the literature. It is indicated for the treatment of varicosities and small or medium size hemangiomas, especially in difficult locations. [3, 5, 7] All lesions evaluated in this study were small, not exceeding 2 cm in diameter, only two lesions had an increased blood flow and in this case recurrence was seen.
Several sclerosing agents can be used, sodium morrhuate and sodium psilato are in disuse since they cause extreme local pain, frequent allergic reactions that may lead to anaphylactic shock. EO and sodium tetradecyl sulfate are the most commonly used sclerosing agents. [17] Improper use of EO may result in side effects such as anaphylaxis, thrombophlebitis, thromboembolism and transient bradycardia. [18] These effects were reported when higher doses were used, in our study quantity injected did not exceed 1 ml and there was only one lesion that presented an ulcer that healed properly after 7 days. Matsumoto et al. [19] suggested that the use of <1 ml of 5% EO may prevent complications.
Lesions size and clinical response in the weeks following sclerotherapy helps to determine drugs dose and number of sessions to complete scleroses a lesion. If during the review appointment there is not a significant reduction in lesions size a new application should be performed. Amount applied must not exceed 1 ml per lesion, and if necessary another sclerotherapy session may be done after 15 days. [10] In this study, the amount applied in most of the lesions was ≤0.25 ml applied in one or two sessions. EO may spread to the cardiovascular system when injected in the interior of arteries. To avoid this complication it is necessary to correctly indicate the use of sclerosing substances, avoiding application in pulsing vascular lesions or with increased flow. [20] Only a patient showed recurrence in two of three treated lesions. During patient reevaluation this lesions showed an increased flow, the reason for recurrence was drug limited action at OHEM site since probably there was systemic dissemination. In low flow recurrent lesions injection of 5% EO could be repeated.
Conclusion
Small size lesions (≤1 cm) regressed in most cases after one or two sessions of sclerotherapy with 5% EO. Drug was able to promote total regression of OHEM with a low recurrence rate of 10%. Thus, it can be stated that treatment with sclerosing agents was effective and this a method of easy application, low cost, low invasiveness with a small rate of recurrence.
